COMMUNIQUÉS West-GlobeNewswire

Spero Therapeutics to Present Data for All Pipeline Programs at the ASM Microbe 2019 Conference
17/06/2019
Twenty-two presentations with data across all pipeline programs, including four oral presentations CAMBRIDGE, Mass., June 17, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage [...]
Hemispherx Biopharma Issues Clinical Update for Ampligen Immuno-oncology Program
17/06/2019
OCALA, Fla., June 17, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma Inc. (NYSE American: HEB) issued its quarterly update on the progress of its ongoing clinical trials evaluating Ampligen’s ability to reprogram tumor [...]
Todos Medical CEO Presented Corporate Update And Roadmap at The LD Micro Conference
17/06/2019
REHOVOT, Israel, June 17, 2019 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and [...]
Ziopharm Oncology Appoints Heidi Hagen to Board of Directors
17/06/2019
Operations Management Leader for Immunex, Dendreon; Co-Founder and Chief Strategy Officer of Vineti BOSTON, June 17, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP), today [...]
Fluidigm Scales Highly Multiplexed Cell Analysis with Introduction of Seven New Metal Markers
17/06/2019
Powering industry-leading CyTOF technology to deliver new insights in translational and clinical research SOUTH SAN FRANCISCO, Calif., June 17, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative [...]
Better Choice Company Broadens Retail Expansion by Placing Kiosks in Highly Trafficked Mall and Shopping Centers
17/06/2019
NEW YORK, June 17, 2019 (GLOBE NEWSWIRE) -- Better Choice Company, Inc. (OTCQB: BTTR) (the “Company” or “Better Choice”), an animal health and wellness CBD company, today announced that it has signed a management [...]
Geron Reports Two Imetelstat Data Presentations at European Hematology Association Annual Congress
17/06/2019
Updated 8-week RBC-TI rate for the Phase 2 portion of IMerge increased to 42%, from 37% in December 2018 Updated 24-week RBC-TI rate for the Phase 2 portion of IMerge increased to 29%, from 26% in December 2018 [...]
Tetra Bio-Pharma Announces PPP003 Program Update Following Type B Meeting With U.S. FDA
17/06/2019
Proposed clinical development pathway confirmed by FDA OTTAWA, June 17, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc ., (“ Tetra ” or the “ Company ”) a leader in cannabinoid-derived drug discovery and development (TSX [...]
JSC Olainfarm Informs About Registration Of New Collateral
17/06/2019
To finance its daily activities and investments Olainfarm Group in the past attracted loan facilities from SEB and ABLV banks. Such information is disclosed in financial statements. This year existing credit agreements [...]
Kevin Harris elected Ducks Unlimited Canada’s 44th president
17/06/2019
New Brunswick conservationist to lead country’s premier wetland conservation organization OAK HAMMOCK MARSH, Man., June 17, 2019 (GLOBE NEWSWIRE) -- Ducks Unlimited Canada (DUC) has elected Kevin Harris as its 44 th [...]
Kevin Harris élu 44e président de Canards Illimités Canada
17/06/2019
Ce conservationniste du Nouveau-Brunswick dirigera le plus prestigieux organisme de conservation des milieux humides du pays marais Oak Hammock (Manitoba), 17 juin 2019 (GLOBE NEWSWIRE) -- Canards Illimités Canada (CIC [...]
Aclaris Therapeutics Announces Positive 6-Month Results from a Phase 2 Open-Label Clinical Trial of ATI-502 Topical in Patients with Androgenetic Alopecia (Male/Female Pattern-Baldness)
17/06/2019
WAYNE, Pa., June 17, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced positive [...]
Calithera Achieves Positive Topline Results in Randomized Phase 2 ENTRATA Study of Telaglenastat with Everolimus in Renal Cell Carcinoma
17/06/2019
-Doubled median progression-free survival (PFS) in heavily pre-treated patients with advanced renal cell carcinoma -Provides first clinical proof of concept for glutaminase inhibitor telaglenastat -Management to host [...]
VBI Vaccines Announces Positive Top-Line Results from PROTECT, a Pivotal Phase 3 Study of Sci-B-Vac®
17/06/2019
Both co-primary endpoints successfully met – including non-inferiority in all adults age ≥18 years, and superiority in adults age ≥ 45 years Seroprotection rates four weeks post-3 rd vaccination of Sci-B-Vac® vs. [...]
Arrayit Corporation Reports Clinical Laboratory Certificate of Deemed Status by the State of California Department of Public Health
17/06/2019
Sunnyvale, June 17, 2019 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC ), a life sciences and personalized medicine company, in accordance with the provisions of the Business and Professions Code has received [...]
Share buy-back week 24/2019
17/06/2019
Announcement 17 June 2019 Coloplast – transactions in connection with share buy-back programme As mentioned in Announcement No. 2/2019 Coloplast has initiated the second part of the share buy-back programme totalling up [...]
BBS announces a share issue of approximately 12.7-16.8 MSEK to expand the owner base in Sweden
17/06/2019
The Board of Directors of BBS – Bioactive Bone Substitutes Oyj (“BBS” or “Company”), an innovator in orthobiologics, has today decided to conduct a share issue based on the authorization granted at the Annual General [...]
Terveystalo's occupational health services to expand: Terveystalo acquires the occupational health operations from Welfare District of Forssa
17/06/2019
Press Release 17 June 2019 Terveystalo will buy the occupational health operations of Welfare District of Forssa by an agreement signed on 17 June 2019. Terveystalo will also become the occupational health care provider [...]
NeuroSearch announces a change to its financial outlook for 2019
17/06/2019
Company announcement 17 June 2019 In its Annual Report 2018, NeuroSearch announced an expected operating loss (on a going-concern assumption) of approximately DKK 4-6 million. The expectations did not include expenses [...]

Pages